Anellovirus genome quantification as a biomarker of immune suppression
The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
1. A method of stimulating the immune system of a human subject in need thereof, comprising
1) obtaining a blood sample from the human subject,
2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is higher than 0.2×10 −4 , and
4) administering a treatment to stimulate the immune system of the human subject.
2. The method of claim 1 , wherein said human subject suffers from transplant rejection.
3. The method of claim 1 , wherein said human subject suffers from an infection.
4. A method of immunosuppressing the immune system of a human subject in need thereof, comprising
1) obtaining a blood sample from the human subject,
2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is lower than 0.2×10 −4 , and
4) administering a treatment to suppress the immune system of the human subject.
5. The method of claim 4 , wherein said human subject suffers from transplant rejection.
6. The method of claim 4 , wherein said human subject suffers from an infection.
7. The method of claim 1 , wherein the level of anellovirus DNA is measured by hybridization with a labeled probe, PCR amplification or sequencing.
8. The method of claim 1 , wherein the level of anellovirus DNA is measured by sequencing said anellovirus DNA.
9. The method of claim 1 , wherein the level of anellovirus DNA is measured by a quantitative sequencing method comprising at least one amplification step with primers comprising at least 12, 15, 20 or 25 consecutive bases of SEQ ID NO: 4 or 5.
10. The method of claim 9 wherein said primers further comprise at least one of:
a functional group for covalent coupling at the 5′ or 3′ end,
a spacer molecule or sequence at the 5′ or 3′ end,
additional sequences as index or tag sequences to perform pre or post additional and general amplification steps not depending on the target sequences to be quantified.
11. The method of claim 1 , wherein the level of anellovirus DNA is measured by massive parallel sequencing.
12. The method of claim 1 , wherein measuring the level of anellovirus DNA in the sample comprises the step of measuring the number of anelloviral sequences in the said biological sample.
13. The method of claim 1 , wherein measuring the level of anellovirus DNA in the sample further comprises the steps of assigning each anellovirus sequence to a specific anellovirus genome and numbering the copies of anellovirus genomes thus identified.
14. The method of claim 13 , wherein measuring the level of anellovirus DNA in the sample further comprises the step of normalizing the number of anellovirus genomes to at least one human or non-human sequence.
15. The method of claim 1 , wherein the level of anellovirus DNA in the sample is determined by quantitative PCR.
16. The method of claim 1 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of at least one consensus anellovirus sequence.
17. The method of claim 1 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of any anelloviral sequence that is between the consensus sequences of SEQ ID No. 4 and SEQ ID No. 5.
18. The method of claim 10 wherein said functional group for covalent coupling at the 5′ or 3′ end is a terminal group comprising a thiol, amine or carboxyl group.
19. The method of claim 4 , wherein the level of anellovirus DNA is measured by hybridization with a labeled probe, PCR amplification or sequencing.
20. The method of claim 4 , wherein the level of anellovirus DNA is measured by sequencing said anellovirus DNA.
21. The method of claim 4 , wherein the level of anellovirus DNA is measured by a quantitative sequencing method comprising at least one amplification step with primers comprising at least 12, 15, 20 or 25 consecutive bases of SEQ ID NO: 4 or 5.
22. The method of claim 21 wherein said primers further comprise at least one of:
a functional group for covalent coupling at the 5′ or 3′ end,
a spacer molecule or sequence at the 5′ or 3′ end,
additional sequences as index or tag sequences to perform pre or post additional and general amplification steps not depending on the target sequences to be quantified.
23. The method of claim 4 , wherein the level of anellovirus DNA is measured by massive parallel sequencing.
24. The method of claim 4 , wherein measuring the level of anellovirus DNA in the sample comprises the step of measuring the number of anelloviral sequences in the said biological sample.
25. The method of claim 4 , wherein measuring the level of anellovirus DNA in the sample further comprises the steps of assigning each anellovirus sequence to a specific anellovirus genome and numbering the copies of anellovirus genomes thus identified.
26. The method of claim 25 , wherein measuring the level of anellovirus DNA in the sample further comprises the step of normalizing the number of anellovirus genomes to at least one human or non-human sequence.
27. The method of claim 4 , wherein the level of anellovirus DNA in the sample is determined by quantitative PCR.
28. The method of claim 4 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of at least one consensus anellovirus sequence.
29. The method of claim 4 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of any anelloviral sequence that is between the consensus sequences of SEQ ID No. 4 and SEQ ID No. 5.
30. The method of claim 22 wherein said functional group for covalent coupling at the 5′ or 3′ end is a terminal group comprising a thiol, amine or carboxyl group.
31. A method comprising
1) obtaining a blood sample from a human subject undergoing an immunomodulation treatment,
2) measuring the level of anellovirus DNA in the sample by a method comprising detecting Torque teno virus (TTV) DNA, Torque teno midi virus (TTMDV) DNA, and Torque teno mini virus (TTMV) DNA,
3) calculating the ratio of anelloviral sequences to the total number of sequences present in the sample, wherein said measured ratio is about 0.2×10 −4 , and
4) continuing the immunomodulation treatment.
32. The method of claim 31 , wherein said human subject suffers from transplant rejection.
33. The method of claim 31 , wherein said human subject suffers from an infection.
34. The method of claim 31 , wherein the level of anellovirus DNA is measured by hybridization with a labeled probe, PCR amplification or sequencing.
35. The method of claim 31 , wherein the level of anellovirus DNA is measured by sequencing said anellovirus DNA.
36. The method of claim 31 , wherein the level of anellovirus DNA is measured by a quantitative sequencing method comprising at least one amplification step with primers comprising at least 12, 15, 20 or 25 consecutive bases of SEQ ID NO: 4 or 5.
37. The method of claim 36 wherein said primers further comprise at least one of:
a functional group for covalent coupling at the 5′ or 3′ end,
a spacer molecule or sequence at the 5′ or 3′ end,
additional sequences as index or tag sequences to perform pre or post additional and general amplification steps not depending on the target sequences to be quantified.
38. The method of claim 31 , wherein the level of anellovirus DNA is measured by massive parallel sequencing.
39. The method of claim 31 , wherein measuring the level of anellovirus DNA in the sample comprises the step of measuring the number of anelloviral sequences in the said biological sample.
40. The method of claim 31 , wherein measuring the level of anellovirus DNA in the sample further comprises the steps of assigning each anellovirus sequence to a specific anellovirus genome and numbering the copies of anellovirus genomes thus identified.
41. The method of claim 40 , wherein measuring the level of anellovirus DNA in the sample further comprises the step of normalizing the number of anellovirus genomes to at least one human or non-human sequence.
42. The method of claim 31 , wherein the level of anellovirus DNA in the sample is determined by quantitative PCR.
43. The method of claim 31 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of at least one consensus anellovirus sequence.
44. The method of claim 31 , wherein measuring the level of anellovirus DNA in the sample comprises the amplification of any anelloviral sequence that is between the consensus sequences of SEQ ID No. 4 and SEQ ID No. 5.
45. The method of claim 37 wherein said functional group for covalent coupling at the 5′ or 3′ end is a terminal group comprising a thiol, amine or carboxyl group.